Mauricio Tohen, MD, DrPH, MBA

Efficacy (NNT) and Tolerability (NNH) of Cariprazine in Bipolar Disorder

Background: Cariprazine is approved to treat manic, mixed, and depressive symptoms of bipolar I disorder. This analysis describes the efficacy and tolerability of cariprazine in bipolar I...

Willie Earley , MD;

Mehul Patel , MD, PharmD;

Mauricio Tohen , MD, DrPH, MBA;

Leslie Citrome , MD;

11/22/2019

Characteristics of Patients in Recovery Versus Patients With Recurrence in a Randomized Placebo-Controlled Study With Aripiprazole Once-Monthly as Maintenance Treatment for Bipolar I Disorder

Aims. To describe the background and clinical characteristics of patients who did versus those who did not have a recurrence of a mood episode during up to 52 weeks of maintenance treatme...

Peter Zhang , PhD;

Ross Baker , PhD, MBA;

Pedro Such , MD;

Jessica Madera , MD;

Mauricio Tohen , MD, DrPH, MBA;

03/01/2019

Cariprazine for Bipolar I Depression: A Randomized Double-Blind Placebo-Controlled Trial

Depressive episodes in bipolar I disorder (BP-1) are associated with increased disability, morbidity, and suicide, and have fewer evidence-based treatment options compared to manic episod...

Trisha Suppes , MD, PhD;

Mauricio Tohen , MD, DrPH, MBA;

Joseph Calabrese , MD;

Willie Earley , MD;

Maria Burgess , MD;

Barbara Khan , MS;

Ludmyla Rekeda , PhD;

Mehul Patel , MD, PharmD;

03/01/2019

Assessment of Functional Recovery After Long-term Aripiprazole Once-Monthly Maintenance Treatment of Bipolar I Disorder

Background: Functional assessment is complex and often overlooked in patients with bipolar I disorder. The Functioning Assessment Short Test (FAST) assesses optimal functioning in these p...

Peter Zhang , PhD;

Ross Baker , PhD, MBA;

Thomas Brown , PhD;

Mauricio Tohen , MD, DrPH, MBA;

Pedro Such , MD;

Jessica Madera , MD;

Craig Surman , MD;

03/01/2019

Efficacy of Cariprazine in Patient Subgroups: Post Hoc Analysis of 3 Randomized, Placebo-Controlled Trials in Patients With Bipolar Depression

Introduction: Cariprazine is a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat bipolar depression. The efficacy of cariprazine in patients wit...

Vladimir Maletic , MD;

Lakshmi Yatham , MBBS, FRCPC, MRCP, MBA;

Rakesh Jain , MD, MPH, RD;

Willie Earley , MD;

Mehul Patel , MD, PharmD;

Mauricio Tohen , MD, DrPH, MBA;

10/08/2020